{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:46:05Z","timestamp":1771512365200,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medcli.2025.107200","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:52:41Z","timestamp":1760017961000},"page":"107200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin stabilizer targeting for transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"165","author":[{"given":"Jo\u00e3o Victor","family":"de Oliveira Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Vitor","family":"Andrade Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan Gadelha","family":"de Abrantes Formiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Henrique","family":"de Oliveira Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabyan Esberard","family":"de Lima Beltr\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Dantas","family":"Tavares de Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107200_bib0375","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0380","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.medcli.2025.107200_bib0390","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin amyloid cardiomyopathy \u2013 current and future therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medcli.2025.107200_bib0395","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11886-024-02172-w","article-title":"Transthyretin cardiac amyloidosis: current and emerging therapies","volume":"27","author":"Patel","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.medcli.2025.107200_bib0400","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","article-title":"Novel drugs targeting transthyretin amyloidosis","volume":"11","author":"Hanna","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.medcli.2025.107200_bib0405","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1021\/acs.jmedchem.1c00099","volume":"64","author":"Cioffi","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.medcli.2025.107200_bib0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153529","article-title":"Tetrabromobisphenol A is an efficient stabilizer of the transthyretin tetramer","volume":"11","author":"Iakovleva","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2025.107200_bib0415","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.4155\/fmc-2021-0248","article-title":"The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?","volume":"13","author":"Zhong","year":"2021","journal-title":"Future Med Chem"},{"key":"10.1016\/j.medcli.2025.107200_bib0420","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/pharmaceutics15041129","article-title":"Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy","volume":"15","author":"Morfino","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.medcli.2025.107200_bib0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25189969","article-title":"A snapshot of the most recent transthyretin stabilizers","volume":"25","author":"Marotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medcli.2025.107200_bib0430","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2025.107200_bib0435","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/s-0043-1764412","article-title":"Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition","volume":"81","author":"Pinto","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.medcli.2025.107200_bib0440","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1097\/MJT.0000000000001296","article-title":"Targeted therapeutics for transthyretin amyloid cardiomyopathy","volume":"30","author":"Campbell","year":"2023","journal-title":"Am J Ther"},{"key":"10.1016\/j.medcli.2025.107200_bib0445","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2025.107200_bib0450","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2025.107200_bib0455","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2025.107200_bib0460","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"Suppl. 1","key":"10.1016\/j.medcli.2025.107200_bib0465","article-title":"Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy","volume":"42","author":"Rettl","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2025.107200_bib0470","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1253\/circj.CJ-24-0733","article-title":"Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy","volume":"89","author":"Kuyama","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.medcli.2025.107200_bib0475","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.recesp.2023.10.009","article-title":"Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis","volume":"77","author":"Peir\u00f3-Avent\u00edn","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.medcli.2025.107200_bib0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107200_bib0485","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0490","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2459\/JCM.0000000000001036","article-title":"Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation","volume":"21","author":"Gospodinova","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.medcli.2025.107200_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0500","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi Amyloidosis Cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.medcli.2025.107200_bib0505","doi-asserted-by":"crossref","DOI":"10.1177\/1179546817730322","article-title":"Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy","volume":"11","author":"Sultan","year":"2017","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0510","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0515","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107200_bib0520","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107200_bib0525","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0530","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0540","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0555","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications","volume":"45","author":"Hellenbart","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medcli.2025.107200_bib0565","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2025.107200_bib0570","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.medcli.2025.107200_bib0575","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/DHPS.S338577","article-title":"Updated evaluation of the safety, efficacy and tolerability of tafamidis in the treatment of hereditary transthyretin amyloid polyneuropathy","volume":"15","author":"Falc\u00e3o de Campos","year":"2023","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.medcli.2025.107200_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.medcli.2025.107200_bib0585","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, a fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medcli.2025.107200_bib0590","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4103\/NRR.NRR-D-24-00056","article-title":"Design and redesign journey of a drug for transthyretin amyloidosis","volume":"20","author":"Pinheiro","year":"2025","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.medcli.2025.107200_bib0595","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-019-08609-z","article-title":"A molecular mechanism for transthyretin amyloidogenesis","volume":"10","author":"Yee","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.medcli.2025.107200_bib0600","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy","volume":"54","author":"Park","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medcli.2025.107200_bib0605","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2025.107200_bib0610","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/00498254.2017.1366575","article-title":"Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats","volume":"48","author":"Lee","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.medcli.2025.107200_bib0615","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1111\/bcp.14773","article-title":"Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis","volume":"87","author":"Huh","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.medcli.2025.107200_bib0620","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0625","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107200_bib0630","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0635","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107200_bib0640","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40520-024-02750-6","article-title":"Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study","volume":"36","author":"Fumagalli","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.medcli.2025.107200_bib0645","first-page":"530","article-title":"Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model","volume":"29","author":"Bruno","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.medcli.2025.107200_bib0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101123","article-title":"Comprehensive geriatric assessment to optimize the management of older patients with transthyretin cardiac amyloidosis","volume":"3","author":"Fumagalli","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.medcli.2025.107200_bib0655","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107200_bib0660","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/MLR.0000000000000011","article-title":"Distinguishing selection bias and confounding bias in comparative effectiveness research","volume":"54","author":"Haneuse","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.medcli.2025.107200_bib0665","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CLEP.S129879","article-title":"Confounding in observational studies based on large health care databases: problems and potential solutions \u2013 a primer for the clinician","volume":"9","author":"N\u00f8rgaard","year":"2017","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0670","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2025.107200_bib0675","first-page":"323","article-title":"The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy","volume":"31","author":"Nikitin","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.medcli.2025.107200_bib0680","first-page":"530","article-title":"Clinical characteristics of wild-type ATTR-CM patients: a machine learning analysis","volume":"29","author":"Bruno","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.medcli.2025.107200_bib0685","article-title":"Tafamidis in early-stage ATTR-CM: safety analysis","volume":"11","author":"Sultan","year":"2017","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0690","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for ATTR-CM: safety monitoring","volume":"45","author":"Hellenbart","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medcli.2025.107200_bib0695","series-title":"Common terminology criteria for adverse events (CTCAE) v6.0","year":"2023"},{"key":"10.1016\/j.medcli.2025.107200_bib0700","series-title":"Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [TAXXX]","year":"2023"},{"key":"10.1016\/j.medcli.2025.107200_bib0705","first-page":"323","article-title":"Value assessment of disease-modifying therapies for ATTR-CM","volume":"31","author":"Nikitin","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.medcli.2025.107200_bib0710","first-page":"1432","article-title":"Cost-effectiveness of patisiran for hereditary ATTR amyloidosis with polyneuropathy","volume":"271","author":"Polistena","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.medcli.2025.107200_bib0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103057","article-title":"RNA-targeting therapies for amyloid transthyretin cardiomyopathy: a systematic review and meta-analysis","volume":"50","author":"Ramos","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.medcli.2025.107200_bib0720","article-title":"Tafamidis\u2013patisiran combination in ATTR-CM: phase 2 results","volume":"13","author":"Judge","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.medcli.2025.107200_bib0725","first-page":"127","article-title":"Healthcare utilization in ATTR-CM: impact of disease-modifying therapies","volume":"30","author":"Siddiqi","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107200_bib0730","first-page":"S1","article-title":"Value assessment framework for rare disease therapies: 2025 update","volume":"28","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.medcli.2025.107200_bib0735","first-page":"589","article-title":"Real-world cost analysis of tafamidis in Germany","volume":"25","author":"M\u00fcller-Tidow","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.medcli.2025.107200_bib0740","series-title":"Tafamidis discontinuation rates 2021\u20132023","year":"2024"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:44:37Z","timestamp":1771508677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325004282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025775325004282"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107200","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin stabilizer targeting for transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107200"}}